





PENNIE & EDMONDS LLP DOCKET NO. 6923-106

Express Mail No.: EL 501 641 171 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

or application:	Exa	Examiner Saunders, D.								
	Art	Unit <u>1642</u>								
sistant Commiss x PATENT API ashington, D.C.	PLICATION					1050 U.S. 09/9288 09/9288				
						n ====				
			a ⊠ continuation filed on July 26, 19		application under 3	37 CFR § 1.53(b), of				
Richard Kolesi	nick and I	Edward H. Sch	nuchman	cord in prior appli	cation)					
16	(inventor(s) currently of record in prior application)									
METHODS FOR	METHODS FOR THE MODULATION OF ACID-SPHINGOMYELINASE-MEDIATED APOPTOSIS (title of invention)									
1.	⊠	The filing	fee is calculated	below:						
	PATENT APPLICATION FEE VALUE									
ТҮРЕ	N	O. FILED	LESS	EXTRA	EXTRA RATE	FEE				
Total Claims		13	-20	0	\$18.00 each	\$ 0.00				
Independent		4	-3	1	\$80.00 each	\$ 80.00				
	Basic Fee					\$ 710.00				
			\$ 270.00							
			\$ 1,060.00							
		Reduction for In ess Concern	- \$ 530.00							
			\$ 530.00							
	_									
2.	Ø	Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.								
3.	⋈	Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. 08/687,707, filed July								
7	26, 1996.									
4a.		New forma	l drawings are enc	losed.						

4b.	⊠	Informal drawings are enclosed.						
5a.		Priority of application no. filed on in is claimed under 35 U.S.C. §119.						
5b.		The certified copy has been filed in prior application no., filed.						
6.	⊠	The prior application is assigned of record to Sloan-Kettering Institute for Cancer Research (Reel 011301, Frame 0391); and Mount Sinai School of Medicine of New York University (Reel 011301, Frame 0403).						
7a.	⊠	A copy of the Power of Attorney (in 2 counterparts) filed in the prior application no. 08/687,707, filed July 26, 1996, is enclosed.						
7b.		A Power of Attorney is enclosed.						
8.		This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.						
9.		The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no						
10.	⊠	Additional enclosures or instructions: Copies of Small Entity Statements for Sloan-Kettering Institute for Cancer Research and Mount Sinai School of Medicine of New York University, filed in connection with priority application no. 08/687,707.						
Date .	Qu	Respectfully submitted,  Just 13,2001  Jealler Leur Briggs 31,232  Geraldine F. Baldwin (Reg. No.)  PENNIE & EDMONDS LLP  1155 Avenue of the Americas						

New York, N.Y. 10036-2711

(212) 790-9090

ß



08-14-01





58

Approved for use through 09/30/00. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Kolesnick

## UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 6923-106 Total Pages

First Named Inventor or Application Identifier

Express Mail Label No. EL 501 641 171 US

					_			
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.					Assistant Commissioner for Patents  ADDRESS TO: Box Patent Application Washington, DC 20231			
1.		ansmittal Form in duplicate t an original, and a duplicate for fee processing)	[To	tal Pages_4]	6.	0	Microfiche Computer Program (Appendix)	
2.		ication (including 3 pp. claims and a 1p. abstract) red arrangement set forth below)	[Tota	I Pages <u>38</u> ]	7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)	
	-Descr	iptive title of the Invention				a.	.   Computer Readable Copy	
	-Cross	Reference to Related Applications					,	
	-Stater	ment Regarding Fed sponsored R&D				b.	.   Paper Copy (identical to computer copy)	
	-Refer	rence to Microfiche Appendix						
្រុំ -Background of the Invention						C.	Statement verifying identity of above copies	
	-Brief Summary of the Invention				ACCOMPANYING APPLICATION PARTS			
	ਜ਼ਿਸ਼ -Brief l	Description of the Drawings (if filed)				7,000 mil 7,1110 7,11 Elo7,110 11 7,1110		
	ार्थ -Detail	led Description of the Invention (including drawings, if filed)					Assignment Papers (cover sheet & document(s))	
	-Brief I	o(s) act of the Disclosure			9.		37 CFR 3.73(b) Statement □ Power of Attorney (when there is an assignee)	
3.	ន្ទី Drawin	ng(s) (35 USC 113) - 7 Figures	[Tota	al Sheets 8]	10.		English Translation Document (if applicable)	
<ul> <li>3.  a Drawing(s) (35 USC 113) - 7 Figures [Total Sheets 8]</li> <li>4.  a Oath or Declaration and Power of Attorney in 2 counterparts [Total Sheets 4]</li> </ul>					11.		Information Disclosure	
	a □ Ne	wly executed (original or copy)			12.		Preliminary Amendment	
		Sopy from a prior application (37 CFR 1.63(d))  (for continuation/divisional with Box 17 completed)			13.	×	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
		[Note Box 5 below]				×	Applicants claim Small Entity status, see 37 C.F.R. § 1.27	
	<sup>₹%</sup> i. □	DELETION OF INVENTORS(S)			(Co	pie	es of small entity statements from 08/687,707/Total Sheets 4	
	#===	Signed statement attached deleting inventor(s) name	ned in	the prior	15.	0	Certified Copy of Priority Document(s)	
_	-	application, see 37 CFR 1.63(d)(2) and 1.33 (b).					(if foreign priority is claimed)	
5.	The er or decl disclos	oration By Reference (useable if Box 4b is checked) tire disclosure of the prior application, from which a laration is supplied under Box 4b, is considered as b sure of the accompanying application and is hereby ince therein.	copy being p	part of the	16.		Other:	
17.	If a CON ⊠ Contin	TINUING APPLICATION, check appropriate box an uation    Divisional    Continuation-in-part					rmation: tion No:- 08/687,707 filed July 26, 1996.	
		18. COF	RES	PONDENCE	ADD	RE	ESS	
	Cus	tomer Number: 20583 (Insert Custome		I.I.III. or Attach bar			or ☐ Correspondence address below	
NA	ME							
AD	DRESS							
CIT	ΓΥ			STATE			ZIP CODE	
		LEPHONE			FAX			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.